Registry of Lobbyists
Janssen Inc.
| Subject matters | Details | Categories |
|---|---|---|
|
Health, Industry
|
An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
|
Regulation
|
|
Economic Development, Health, Industry, Intellectual Property, Research and Development, Science and Technology
|
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
|
Policies or Program
|
|
Economic Development, Health, Industry, International Development
|
Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry
|
Canadian Drug Agency: Specifically, the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
|
Health, Industry, Internal Trade
|
Communications regarding the maintenance of domestic supply of essential drug products.
|
Policies or Program
|
|
Economic Development, Health, Industry, Intellectual Property, International Trade
|
Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
|
Legislative Proposal, Bill or Resolution
|
|
Health
|
COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic.
|
Policies or Program
|
|
Health
|
Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector.
|
Policies or Program
|
|
Health, Industry, International Trade
|
Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Intellectual Property
|
Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
|
Regulation, Policies or Program
|
|
Economic Development, Health, Industry
|
Incentives and programs to attract and support manufacturing activities in Canada
|
Policies or Program
|
|
Economic Development, Health, Industry, Research and Development, Science and Technology, Taxation and Finance
|
Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.
|
Policies or Program
|
|
Health, Industry
|
Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration).
|
Regulation
|
|
Health
|
Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program.
|
Policies or Program, Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Intellectual Property, Research and Development
|
Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D.
|
Legislative Proposal, Bill or Resolution, Regulation, Policies or Program
|
|
Health, Industry
|
Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.
|
Regulation
|